About Amygdala Neurosciences
Amygdala Neurosciences is a company based in San Francisco (United States) founded in 2015 by Peter Strumph.. Amygdala Neurosciences has raised $7.05 million across 6 funding rounds from investors including NIH, HHS and ABMRF/The Foundation for Alcohol Research. Amygdala Neurosciences offers products and services including ALDH2 Inhibitors. Amygdala Neurosciences operates in a competitive market with competitors including Indivior, Ethypharm, Braeburn, Cessation Therapeutics and Aelis Farma, among others.
- Headquarter San Francisco, United States
- Founders Peter Strumph
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amygdala Neurosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.05 M (USD)
in 6 rounds
-
Latest Funding Round
-
Investors
NIH
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amygdala Neurosciences
Amygdala Neurosciences offers a comprehensive portfolio of products and services, including ALDH2 Inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitors aimed at treating substance use disorders by reducing cravings.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Amygdala Neurosciences
Amygdala Neurosciences has successfully raised a total of $7.05M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(27 Apr 2015)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series A - Amygdala Neurosciences | Valuation |
investors |
|
| Aug, 2023 | Amount | Grant - Amygdala Neurosciences | Valuation |
investors |
|
| Sep, 2021 | Amount | Grant - Amygdala Neurosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amygdala Neurosciences
Amygdala Neurosciences has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and ABMRF/The Foundation for Alcohol Research. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research on alcohol effects is funded by this foundation.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amygdala Neurosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Amygdala Neurosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amygdala Neurosciences Comparisons
Competitors of Amygdala Neurosciences
Amygdala Neurosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, Braeburn, Cessation Therapeutics and Aelis Farma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Long-acting therapies for opioid addiction and chronic pain are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapy based vaccines to manage addictions
|
|
| domain | founded_year | HQ Location |
Developer of small molecule drugs targeting CB1 receptor for CNS diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amygdala Neurosciences
Frequently Asked Questions about Amygdala Neurosciences
When was Amygdala Neurosciences founded?
Amygdala Neurosciences was founded in 2015.
Where is Amygdala Neurosciences located?
Amygdala Neurosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Amygdala Neurosciences?
Peter Strumph is the current CEO of Amygdala Neurosciences. They have also founded this company.
Is Amygdala Neurosciences a funded company?
Amygdala Neurosciences is a funded company, having raised a total of $7.05M across 6 funding rounds to date. The company's 1st funding round was a Grant of $224.5K, raised on Apr 27, 2015.
What does Amygdala Neurosciences do?
Amygdala Neurosciences was founded in 2015 and is based in San Francisco, United States. Focus is placed on the biotechnology sector, where therapies for substance use disorders are developed. The lead candidate, ANS-6637, functions as an aldehyde dehydrogenase (ALDH2) inhibitor targeting seeking behavior, craving, and relapse. Phase I studies have been completed, with preparations underway for a phase II trial.
Who are the top competitors of Amygdala Neurosciences?
Amygdala Neurosciences's top competitors include Indivior, Ethypharm and Aelis Farma.
What products or services does Amygdala Neurosciences offer?
Amygdala Neurosciences offers ALDH2 Inhibitors.
Who are Amygdala Neurosciences's investors?
Amygdala Neurosciences has 4 investors. Key investors include NIH, HHS, ABMRF/The Foundation for Alcohol Research, and National Institute on Alcohol Abuse and Alcoholism.